Women’s health company Oriva Therapeutics has appointed Dr Agnès Arbat as Chief Executive Officer. 

Arbat joins with more than 25 years of experience in the pharmaceutical industry, which Oriva says demonstrate a strong track record across clinical development, medical affairs and commercial strategy in women’s health. 

Arbat was previously Co-Founder and CEO of Oxolife, a specialist biotech focused on female fertility, and before that led the Women’s Health and Cardiovascular medical team at Bayer and worked at Organon in Medical Affairs for Women’s Health. 

Alongside her role as CEO, Arbat will serve as Oriva’s Chief Medical Officer. 

“Oriva’s assets have the potential to deliver best-in-class treatments for women worldwide suffering from common, painful and debilitating gynaecological conditions – thus addressing clear and significant unmet medical needs,” Arbat said. 

“As CEO and CMO, I look forward to working with the company’s expert senior leadership team to progress its fantastic programmes through development. With clinical activity already underway and strong backing from Asabys Partners, we are well positioned to execute and deliver meaningful progress for patients.” 

“Agnès’ deep scientific expertise in women’s health and her strong track record of strategic leadership makes her exceptionally well qualified to lead Oriva as it advances its programmes and accelerates through its next phase of growth,” added Clara Campàs, Co-Founder and Managing Partner at Asabys Partners. 

Oriva was founded earlier this year and is currently advancing its clinical-stage pipeline. Its lead asset ORV-362 is a first-in-class, non-hormonal, disease-modifying therapy for endometriosis, which affects about 10% of women of reproductive age worldwide.